Key result
Statin use is linked to ~33% lower 12-month mortality in patients with first-episode depression.
Why the study?
NICE guidance endorses statins for broader populations including those with severe mental illness, but the safety and risk/benefit balance of statins in depression is not established.
Does statin use reduce all-cause mortality or adverse events in primary care patients with first-episode depression?
Cohort (n=1,050,105)
Yes
Does statin use reduce all-cause mortality or adverse events in primary care patients with first-episode depression?
Statin use in primary care patients with depression does not increase neuropsychiatric adverse events and is associated with reduced all-cause mortality, supporting guidelines for their broader use in primary CVD prevention.
Answers are grounded in this paper and cite their sources.
Statin use was associated with lower mortality without excess adverse events in first-episode depression; hypothesis-generating and requires randomized confirmation before practice change.
Background New National Institute for Health and Care Excellence (NICE) guidance endorses the prescription of statins in larger population groups for the prevention of cardiovascular and cerebrovascular morbidity and mortality, especially in people with severe mental illness. However, the evidence base for their safety and risk/benefit balance in depression is not established. Objectives This study aims to assess the real-world mortality and adverse events of statins in depressive disorders. Methods Population-based, nationwide (England), between-subject, cohort study. We used electronic health records (QResearch database) of people aged 18–100 years with first-episode depression, registered with English primary care practices over January 1998–August 2020 for 12(+) months, divided into statin users versus non-users. Primary safety outcomes included all-cause mortality and any adverse event measured at 2, 6 and 12 months. Multivariable logistic regression was employed to control for several potential confounders and calculate adjusted ORs (aORs) with 99% CIs. Findings From over 1 050 105 patients with depression (42.64% males, mean age 43.23±18.32 years), 21 384 (2.04%) died, while 707 111 (67.34%) experienced at least one adverse event during the 12-month follow-up. Statin use was associated with lower mortality over 12 months (range aOR 2–12months 0.66–0.67, range 99% CI 0.60 to 0.73) and with lower adverse events over 6 months (range aOR 2–6months 0.90–0.96, range 99% CI 0.91 to 0.99), but not at 1 year (aOR 12months 0.99, 99% CI 0.96 to 1.03). No association with any other individual outcome measure (ie, any other neuropsychiatric symptoms) was identified. Conclusions We found no evidence that statin use among people with depression increases mortality or other adverse events. Clinical implications Our findings support the safety of updated NICE guidelines for prescribing statins in people with depressive disorders.
No takes yet. Share an insight, caveat, or question.
Giorgi et al. (2024) conducted a cohort in First-episode depression (n=1,050,105). Statin use vs. Statin non-use was evaluated on All-cause mortality at 12 months (aOR 0.67, 95% CI 0.65-0.73). Statin use was associated with a 33% reduction in the odds of all-cause mortality over 12 months compared to non-use in patients with first-episode depression.
Synapse has enriched 10 related papers. Consider them for comparative context: